State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Anal Chim Acta. 2012 Jan 20;711:60-8. doi: 10.1016/j.aca.2011.10.058. Epub 2011 Nov 7.
A rapid, sensitive, specific and accurate analytical method of ultra-fast liquid chromatography combined with tandem mass spectrometry (UFLC-MS/MS) was established for simultaneous quantitative analysis of 16 distinct endogenous estrogens and their metabolites (EMs) in postmenopausal female urine. The quantitative method utilized a hydrolysis/extraction/derivatization step and a UFLC system to achieve separation in 16 min. The lower limit of quantitation for each estrogen metabolite was 2 pg mL(-1) with the percent recovery of a known added amount of estrogen at 93.2-109.3%. The intra-batch accuracy and precision for all analytes were 87.5-107.7% and 0.6-11.7%, respectively, while inter-batch accuracy and precision were 87.0-105.8% and 1.2-10.2%, respectively. Using this developed and validated method, the comprehensive metabolic profiling of 16 EMs in urine samples of 86 postmenopausal female breast cancer patients and 36 healthy controls was investigated by systematic statistical analysis. As a result, the circulating levels of 6 EMs were found to be different by a comparison of patients and healthy controls. The parent estrogens, estrone (E1) and 17β-estradiol (E2), as well as 2-hydroxyestradiol (2-OHE2) and 4-hydroxyestradiol (4-OHE2) were produced in higher abundance, whereas 16α-hydroxyestrone (16α-OHE1) and 2-methoxyestradiol (2-MeOE2) were decreased in the breast cancer group. 2-OHE2 and 4-OHE2 in particular showed significant elevation in patients, which are consistent with the carcinogenic mechanism hypothesis that catechol estrogens can react with DNA via quinones, resulting in mutations to induce breast cancer. Thus, 2,4-hydroxylation may be the dominant metabolic pathway for parent estrogens rather than 16α-hydroxylation. The lower level of 2-MeOE2 in the breast cancer group was believed to correlate with its protective effect against tumor formation. This study could provide valuable information on the association of the EM metabolic pathway with carcinogenesis as well as identify potential biomarkers for estrogen-induced breast cancer risk.
建立了超快速液相色谱-串联质谱法(UFLC-MS/MS)快速、灵敏、特异、准确的同时定量分析绝经后女性尿液中 16 种内源性雌激素及其代谢物(EMs)的分析方法。该定量方法采用水解/提取/衍生化步骤和 UFLC 系统,在 16 分钟内实现分离。每种雌激素代谢物的定量下限为 2 pg mL(-1),已知添加量的雌激素回收率为 93.2-109.3%。所有分析物的批内精密度和准确度分别为 87.5-107.7%和 0.6-11.7%,而批间精密度和准确度分别为 87.0-105.8%和 1.2-10.2%。使用该开发和验证的方法,通过系统的统计分析,对 86 例绝经后女性乳腺癌患者和 36 例健康对照者尿液中 16 种 EMs 的综合代谢谱进行了研究。结果发现,与健康对照组相比,患者中 6 种 EM 的循环水平存在差异。雌酮(E1)和 17β-雌二醇(E2)等母体雌激素以及 2-羟基雌二醇(2-OHE2)和 4-羟基雌二醇(4-OHE2)的含量较高,而 16α-羟基雌酮(16α-OHE1)和 2-甲氧基雌二醇(2-MeOE2)的含量则降低。特别是 2-OHE2 和 4-OHE2 在患者中明显升高,这与儿茶酚雌激素可以通过醌与 DNA 反应,导致突变引发乳腺癌的致癌机制假说一致。因此,2,4-羟化可能是母体雌激素的主要代谢途径,而不是 16α-羟化。乳腺癌组中 2-MeOE2 水平较低,可能与其对肿瘤形成的保护作用有关。本研究可为雌激素代谢途径与致癌作用的相关性提供有价值的信息,并为雌激素诱导的乳腺癌风险识别潜在的生物标志物。